Morgan Stanley’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.12M | Buy |
486,893
+12,475
| +3% | +$80K | ﹤0.01% | 4420 |
|
|
2025
Q1 | $1.68M | Buy |
474,418
+10,198
| +2% | +$36.1K | ﹤0.01% | 4716 |
|
|
2024
Q4 | $1.75M | Sell |
464,220
-14,045
| -3% | -$53.1K | ﹤0.01% | 4795 |
|
|
2024
Q3 | $1.55M | Sell |
478,265
-446,194
| -48% | -$1.45M | ﹤0.01% | 4793 |
|
|
2024
Q2 | $1.76M | Sell |
924,459
-1,146,194
| -55% | -$2.18M | ﹤0.01% | 4645 |
|
|
2024
Q1 | $5.88M | Sell |
2,070,653
-3,589,833
| -63% | -$10.2M | ﹤0.01% | 3793 |
|
|
2023
Q4 | $83.3M | Buy |
5,660,486
+4,708,367
| +495% | +$69.3M | ﹤0.01% | 1925 |
|
|
2023
Q3 | $17.4M | Sell |
952,119
-99,727
| -9% | -$1.83M | ﹤0.01% | 2613 |
|
|
2023
Q2 | $22.7M | Buy |
1,051,846
+149,299
| +17% | +$3.22M | ﹤0.01% | 2352 |
|
|
2023
Q1 | $26.5M | Buy |
902,547
+418,078
| +86% | +$12.3M | ﹤0.01% | 2129 |
|
|
2022
Q4 | $17.9M | Buy |
484,469
+215,399
| +80% | +$7.96M | ﹤0.01% | 2453 |
|
|
2022
Q3 | $7.58M | Buy |
269,070
+225,964
| +524% | +$6.36M | ﹤0.01% | 3261 |
|
|
2022
Q2 | $829K | Buy |
43,106
+761
| +2% | +$14.6K | ﹤0.01% | 5133 |
|
|
2022
Q1 | $544K | Buy |
+42,345
| New | +$544K | ﹤0.01% | 5356 |
|